Welcome to the BASIL-3 Trial Webpage

*** Following the MHRA statement released on the 4th June 2019, BASIL-3 will be re-opening to recruitment as per this statement ***

The Expert Advisory Group for the MHRA published a report advising trials such as BASIL-3 should consider resuming recruitment.  The was reflected in the MHRA MDA (MDA/2019/023) stating the use of paclitaxel devices should still be considered for the treatment of CLTI in accordance to NICE. 

The Global Vascular Guidelines released new guidelines on the management of CLTI (June 2019) which included the following statement:

the risks and benefits of treatment for CLTI, including drug-eluting devices, need to be examined with appropriately controlled prospective studies that are specific to the CLTI population, the execution of randomised controlled-trials involving PTX-eluting devices in CLTI, with appropriate safety monitoring and regulatory oversight are important to the vascular community. Page 104S, Conte et al, GVG on management of CLTI June 2019

The GVG is endorsed by the VSGBI, BSIR and BSET.


Basil-3 is a multi-centre randomised controlled trial of clinical and cost-effectiveness of drug coated balloons, drug eluting stents, and plain balloon angioplasty with bail-out bare metal stent revascularisation strategies for severe limb ischaemia secondary to femoro-popliteal disease. Severe limb ischemia is the most serious and debilitating form of lower limb peripheral artery disease and is a seriously disabling, life and limb threatening, condition. The aim of BASIL-3 is to evaluate the clinical efficacy and cost-effectiveness of the interventions for people with severe limb ischaemia.


nihr_colourThe BASIL-3 Trial is funded by a NIHR Health Technology Assessment grant (project number 13/81/02).

Trial Progress

Basil-3 officially began its 3-year recruitment phase in February 2016, however due to receiving regulatory approval ahead of schedule, the lead centre (Heart of England NHS Foundation Trust) successfully entered the trial's first two participants during January of 2016. 

As of 13 Jun 2019, a total of 34 clinical centres are open to recruit to the Basil-3 trial; 29 in England, 3 in Scotland, and 2 in Wales.  All of the 34 clinical centres have cumulatively recruited 411 participants.  Once recruitment is resumed we hope to open two more centres in the next six months.  

Basil-3 Trial Centres


Clinical centres currently open to recruit to Basil-3

 Centre name Local PI Opened

North Cumbria University Hospitals 

Mr Ron Eifell


Royal Cornwall Hospitals

Mr Harvey Chant


Heart of England NHS FT

Prof. Andrew Bradbury


Sheffield Teaching Hospitals

Dr Stephen Goode


Pennine Acute Hospitals

Dr Khalid Bashaeb


County Durham and Darlington

Mr Philip Davey


East Kent Hospitals

Dr Neelan Das


Colchester Hospital University

Dr Nagendra Thayur 


Dorset County Hospital

Mr James Metcalfe 


Imperial College Healthcare

Prof. Alun Davies 


Aneurin Bevan Health Board

Mr Christopher Twine 


United Lincolnshire Hospitals

Dr Geurino Centini 


Russell's Hall Hospital (Dudley)

Mr Simon Hobbs


Nottingham University Hospitals

Dr Said Habib


Basildon Hospital

Dr Jeremy Rabouhans


University Hospitals of North Midlands

Dr John Asquith


Freeman Hospital (Newcastle)

Prof. Gerard Stansby


Frimley Park Hospital

Mr Patrick Chong


Royal Infirmary of Edinburgh

Dr Graeme Weir


Leeds General Infirmary

Dr Jai Patel


Royal Wolverhampton Hospitals

Mr Simon Hobbs


Leicester Royal Infirmary

Mr Robert Davies


University Hospital of Wales

Dr Richard White


Dumfries and Galloway Royal Infirmary

Mr Joseph Sathianathan


Royal Sussex County Hospital

Mr Mario Caruana


Hull Royal Infirmary

Prof. Ian Chetter


St. Thomas' Hospital

Mr Hany Zayed


Southmead Hospital (Bristol)

Dr Alexander Horsch


Royal Bournemouth

Mr Lasantha Wijesinghe


University Hospital of South Manchester

Mr Ray Ashleigh


Manchester Royal Infirmary

Mr Tawqeer Rashid


Forth Valley Royal Hospital

Dr Nik Arestis


St. George's Hospital

Dr Raj Das


Royal Berkshire

Dr Farhan Ahmad 



You can also see our clinical centres on the map.

The Basil-3 trial team are still accepting expressions of interest from UK-based vascular centres. NHS Trusts in England and Health Boards in the devolved nations should contact the Basil-3 trial office with the name of their proposed Principal Investigator to begin the start-up process for their site. We would typically expect a site Principal Investigator to be a Consultant Interventional Radiologist or a Consultant Vascular Surgeon with prior clinical research experience. Please see the contact us page for details of how to get in touch.

Current Basil-3 Recruitment (end of DEC 2018)

 Last recruitment graph before pause

For a more in depth overview of recruitment to Basil-3, visit our recruitment page.